CARMUSTINE FOR INJECTION USP DIN 02531879
Health Canada record
| Active ingredient(s) | CARMUSTINE 100 MG |
|---|---|
| Dosage form | Powder For Solution |
| Route | Intravenous |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | L01AD01 CARMUSTINE |
| Original market date | 18-May-2023 |
| Current status date | 18-May-2023 |
| Source | Health Canada DPD |
Establishment licence of the holder
Sterimax Inc — licence 100925, currently licensed, last inspection rating C (2024-05-13).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing CARMUSTINE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 00297763 | BICNU | MARCAN PHARMACEUTICALS INC | Powder For Solution | CARMUSTINE 100 MG | Marketed |
| 02555093 | BICNU | MARCAN PHARMACEUTICALS INC | Solution | CARMUSTINE 100 MG | Cancelled Post Market |
| 02238985 | GLIADEL WAFER | EISAI LIMITED | Wafer | CARMUSTINE 7.7 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 29270 | 2022-10-21 | Abbreviated New Drug Submission (ANDS) |
International API supply for CARMUSTINE
7 valid EDQM Certificates of Suitability from 7 holders. 12 active FDA Drug Master Files.
Request a quote for CARMUSTINE FOR INJECTION USP